nexNeuro

A novel stimulation method, the first potential therapy to target the spinal cord instead of the brain, may offer an effective and less invasive approach for Parkinson’s disease treatment, according to pre-clinical data published in the journal Science by researchers at Duke University Medical Center.

Researchers developed a prosthetic device that applies electrical stimulation to the dorsal column in the spinal cord, which is a main sensory pathway carrying tactile information from the body to the brain.

The device was attached to the surface of the spinal cord in mice and rats with depleted levels of the chemical dopamine — mimicking the biologic characteristics of someone with Parkinson’s disease along with the impaired motor skills seen in advanced stages of the disease.

When the device was turned on, the dopamine-depleted animals’ slow, stiff movements were replaced with the active behaviors of healthy mice and rats. Improved movement was typically observed within 3.35 seconds after stimulation.

“We see an almost immediate and dramatic change in the animal’s ability to function when the device stimulates the spinal cord,” says senior study investigator Miguel Nicolelis, MD, PhD, the Anne W. Deane Professor of Neuroscience at Duke.

“Moreover, it is easy to use, significantly less invasive than other alternatives to medication, such as deep brain stimulation, and has the potential for widespread use in conjunction with medications typically used to treat Parkinson’s disease.”

Researchers tested mice and rats with acute and chronic dopamine deficit using varying levels of electrical stimulation and in combination with different doses of dopamine replacement therapy, also known as 3,4-dihydroxy-L-phenylalanine or L-DOPA, to determine the most effective pairing.

When the device was used without additional medication, Parkinsonian animals were 26 times more active. When stimulation was coupled with medication, only two L-DOPA doses were needed to produce movement compared to five doses when the medication was used by itself.

“This work addresses an important need because people living with Parkinson’s disease face a difficult reality — L-Dopa will eventually stop managing the symptoms,” explains Romulo Fuentes, a postdoctoral fellow at Duke University and lead author of the study.

“Patients are left with few options for treatment, including electrical stimulation of the brain, which is appropriate for only a subset of patients.”